Do oral contraceptive pills really protect against venous thromboembolism, especially in polycystic ovary syndrome patients? Prescription bias or not?
Kasapoglu, T.
American Journal of Obstetrics and Gynecology 209(1): 73-74
2013
ISSN/ISBN: 1097-6868 PMID: 23462511 DOI: 10.1016/j.ajog.2013.02.033Document Number: 565828
Document emailed within 0-6 h
Related Documents
Bhattacharya, S.M.; Jha, A. 2012: Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome Fertility and Sterility 98(4): 1053-1059Ozmen, B.; Sükür, Y.E.; Seval, M.M.; Ateş, C.; Atabekoğlu, C.S.; Sönmezer, M.; Berker, B. 2014: Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection European Journal of Obstetrics Gynecology and Reproductive Biology 183: 137-140
Bhattacharya, S.M.; Jha, A.; DasMukhopadhyay, L. 2016: Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 132(2): 210-213
Odlind, V.; Milsom, I.; Persson, I.; Victor, A. 2002: Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstetricia et Gynecologica Scandinavica 81(6): 482-490
Bird, S.T.; Hartzema, A.G.; Brophy, J.M.; Etminan, M.; Delaney, J.A.C. 2013: Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis Cmaj: Canadian Medical Association Journal 185(2): E115-E120
Namli Kalem, M.üb.; Hizli, D.; Kamalak, Z.; Kösüs, A.; Kösüs, N.; Turhan, N.ün.; Kafali, H. 2016: Effect of combined oral contraceptive use on serum 25-hydroxy vitamin D levels and ultrasound parameters in patients with polycystic ovary syndrome Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 32(4): 281-284
Ozgurtas, T.; Oktenli, C.; Dede, M.; Tapan, S.; Kenar, L.; Sanisoglu, S.Y.; Yesilova, Z.; Yenen, M.C.; Erbil, M.K.; Baser, I. 2008: Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS) Atherosclerosis 200(2): 336-344
Kahraman, K.; Sükür, Y.E.; Atabekoğlu, C.S.; Ateş, C.; Taşkın, S.; Cetinkaya, S.E.; Tolunay, H.E.; Ozmen, B.; Sönmezer, M.; Berker, B.ül. 2014: Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial Archives of Gynecology and Obstetrics 290(2): 321-328
Kriplani, A.; Periyasamy, A.J.; Agarwal, N.; Kulshrestha, V.; Kumar, A.; Ammini, A.C. 2010: Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome Contraception 82(2): 139-146
Harmanci, A.; Cinar, N.; Bayraktar, M.; Yildiz, B.O. 2013: Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome Clinical Endocrinology 78(1): 120-125
Raj, S.G.; Raj, M.H.; Talbert, L.M.; Sloan, C.S.; Hicks, B. 1982: Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome Obstetrics and Gynecology 60(1): 15-19
Minozzi, M.; Costantino, D.; Guaraldi, C.; Unfer, V. 2011: The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 27(11): 920-924
Iwata, M.Chiharu.; Porquere, L.; Sorpreso, I.C.Espósito.; Baracat, E.C.; Soares Júnior, Jé.Maria. 2015: Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome Revista da Associacao Medica Brasileira 61(3): 215-219
Cinar, N.; Harmanci, A.; Demir, B.; Yildiz, B.O. 2012: Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study Human Reproduction 27(6): 1840-1845
Banaszewska, B.; Spaczyński, R.Z.; Ozegowska, K.; Pawelczyk, L. 2011: The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome Ginekologia Polska 82(6): 430-435
Vasilakis, C.; Jick, S.S.; Jick, H. 1999: The risk of venous thromboembolism in users of postcoital contraceptive pills Contraception 59(2): 79-83
Markantes, G.; Saltamavros, A.D.; Vervita, V.; Armeni, A.K.; Karela, A.; Adonakis, G.; Decavalas, G.; Georgopoulos, N.A. 2011: Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 27(12): 971-977
Braithwaite, I.; Shirtcliffe, P.; Weatherall, M.; Beasley, R. 2016: Anti-androgen contraceptive pills and higher risk of venous thromboembolism New Zealand Medical Journal 129(1430): 102-104
Uras, R.; Orrù, M.; Pani, F.; Marotto, M.F.; Pilloni, M.; Guerriero, S.; Etzi, R.; Zedda, P.; Sorge, R.; Lello, S.; Melis, G.B.; Paoletti, A.M. 2010: Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome Contraception 82(2): 131-138
Jick, S.S. 2015: Fresh evidence confirms links between newer contraceptive pills and higher risk of venous thromboembolism Bmj 350: H2422